BUZZ-India's drugmakers drop on uncertainty over US tariff threats

India's pharmaceutical companies .NIPHARM drop 1.7%, with 19 of the 20 constituents trading in the red

The index has lost about 7.6% over two weeks, pressured by the uncertainty over U.S. tariffs following President Donald Trump's plans to levy at least 25% tariff on pharmaceutical imports

The United States is India's biggest pharmaceuticals market

Domestic drugmakers are hoping that discussions between the U.S. and India will help them steer clear of Trump's tariff threat, a trade association says

Indian pharma companies to remain volatile and could see further pressure due to U.S. tariff, says Citi Research

Citi prefers drugmakers such as Divi's Laboratories DIVI.NS, Sun Pharma SUN.NS and Torrent Pharma TORP.NS with lower exposure to U.S. generics

The pharma index is down 2% for the week, against the Nifty's 0.6% drop, making it one of the worst-performing sectors